Skip to main content
SpringerLink
Log in

Microbiome in Idiopathic Pulmonary Fibrosis

  • Chapter
  • First Online:
Microbiome in Inflammatory Lung Diseases

  • 522 Accesses

Abstract

It is believed that Idiopathic Pulmonary Fibrosis (IPF) is an age-related chronic, progressive, and histopathologically associated fibrosing interstitial lung disorder which primarily affects the elderly. Despite tremendous progress in our knowledge of pathophysiology of diseases, we still do not know the possible causes of IPF. According to current research evidences, it is proposed that IPF may develop genotype as a result of repeated alveolar damage causing an abnormal wound-healing response. Genomic variations in epithelial integrity and host defence genes put people at risk for IPF, whereas immunosuppression and overt respiratory infection are supposed to have a high death rate. The role of infection in disease etiopathogenesis has long been suspected and its progression, or as a cause of acute aggravation, although preliminary investigations using classic culture procedures have formed inconsistent findings. Current approach of culture-independent microbiological analysis procedures to IPF patients has previously revealed various unacknowledged variations in lung microbiome and also a high microbial burden in bronchoalveolar lavage (BAL) in patients with IPF. However, connection does not always imply causation. Furthermore, lung microbiome is still incompletely defined, and more studies need to be done to explore species other than viruses and bacteria, such as fungus. The knowledge of microbiome’s role in aetiology and IPF progression might leads to its modification, allowing targeted therapeutic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Anand S, Mande SS (2018) Diet, microbiota and gut-lung connection. Front Microbiol 9:2147

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bacci G, Taccetti G, Dolce D, Armanini F, Segata N, Di Cesare F et al (2020) Untargeted metagenomic investigation of the airway microbiome of cystic fibrosis patients with moderate-severe lung disease. Microorganisms 8(7):1003

    Article  CAS  PubMed Central  Google Scholar 

  3. Beck JM, Young VB, Huffnagle GB (2012) The microbiome of the lung. Transl Res 160(4):258–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K (2016) Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med 16(1):174

    Article  PubMed  PubMed Central  Google Scholar 

  5. Blanchard AC, Waters VJ (2019) Microbiology of cystic fibrosis airway disease. Semin Respir Crit Care Med 40(6):727–736

    Article  PubMed  PubMed Central  Google Scholar 

  6. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P et al (2019) Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med 7(10):907–920

    Article  PubMed  Google Scholar 

  7. Carney SM, Clemente JC, Cox MJ, Dickson RP, Huang YJ, Kitsios GD et al (2020) Methods in lung microbiome research. Am J Respir Cell Mol Biol 62(3):283–299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Caverly LJ, Zhao J, LiPuma JJ (2015) Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection. Pediatr Pulmonol 50(Suppl 40):S31–S38

    Article  PubMed  Google Scholar 

  9. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ et al (2014) Antibiotic management of lung infections in cystic fibrosis. I. the microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 11(7):1120–1129

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chunxi L, Haiyue L, Yanxia L, Jianbing P, Jin S (2020) The gut microbiota and respiratory diseases: new evidence. J Immunol Res 2020:2340670

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cribbs SK, Beck JM (2017) Microbiome in the pathogenesis of cystic fibrosis and lung transplant-related disease. Transl Res 179:84–96

    Article  CAS  PubMed  Google Scholar 

  12. Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, Hampton TH et al (2020) Lung function and microbiota diversity in cystic fibrosis. Microbiome. 8(1):45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. de Almeida OGG, Capizzani C, Tonani L, Grizante Barião PH, da Cunha AF, De Martinis ECP et al (2020) The lung microbiome of three Young Brazilian patients with cystic fibrosis colonized by fungi. Front Cell Infect Microbiol 10:598938

    Article  PubMed  PubMed Central  Google Scholar 

  14. Dickson RP (2016) The microbiome and critical illness. Lancet Respir Med 4(1):59–72

    Article  PubMed  Google Scholar 

  15. Dmitrijeva M, Kahlert CR, Feigelman R, Kleiner RL, Nolte O, Albrich WC et al (2021) Strain-resolved dynamics of the lung microbiome in patients with cystic fibrosis. MBio 12(2):e02863–e02820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P (2018) Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol 68-69:404–421

    Article  CAS  PubMed  Google Scholar 

  17. Fastrès A, Felice F, Roels E, Moermans C, Corhay JL, Bureau F et al (2017) The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies. Int J Mol Sci 18(12):2735

    Article  PubMed Central  Google Scholar 

  18. Flume PA, Chalmers JD, Olivier KN (2018) Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 392(10150):880–890

    Article  PubMed  PubMed Central  Google Scholar 

  19. Françoise A, Héry-Arnaud G (2020) The microbiome in cystic fibrosis pulmonary disease. Genes 11(5):536

    Article  PubMed Central  Google Scholar 

  20. Han MK, Huang YJ, Lipuma JJ, Boushey HA, Boucher RC, Cookson WO et al (2012) Significance of the microbiome in obstructive lung disease. Thorax 67(5):456–463

    Article  PubMed  Google Scholar 

  21. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN et al (2014) Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2(7):548–556

    Article  PubMed  PubMed Central  Google Scholar 

  22. Heirali AA, Acosta N, Storey DG, Workentine ML, Somayaji R, Laforest-Lapointe I et al (2019) The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome. J Cyst Fibros 18(6):829–837

    Article  CAS  PubMed  Google Scholar 

  23. Héry-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM (2019) The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis? J Cyst Fibros 18(1):13–21

    Article  PubMed  Google Scholar 

  24. Huang YJ, LiPuma JJ (2016) The microbiome in cystic fibrosis. Clin Chest Med 37(1):59–67

    Article  CAS  PubMed  Google Scholar 

  25. Invernizzi R, Wu BG, Barnett J, Ghai P, Kingston S, Hewitt RJ et al (2021) The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 203(3):339–347

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M (2020) Molecular mechanisms: connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma. Int J Mol Sci 21(4):1525

    Article  CAS  PubMed Central  Google Scholar 

  27. Kitsios GD, Rojas M, Kass DJ, Fitch A, Sembrat JC, Qin S et al (2018) Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. Thorax 73(5):481–484

    Article  PubMed  Google Scholar 

  28. Lipinski JH, Moore BB, O’Dwyer DN (2020) The evolving role of the lung microbiome in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 319(4):L675–Ll82

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lira-Lucio JA, Falfán-Valencia R, Ramírez-Venegas A, Buendía-Roldán I, Rojas-Serrano J, Mejía M et al (2020) Lung microbiome participation in local immune response regulation in respiratory diseases. Microorganisms. 8(7):1059

    Article  CAS  PubMed Central  Google Scholar 

  30. Lynch SV (2016) The lung microbiome and airway disease. Ann Am Thorac Soc 13 Suppl 2(Suppl 5):S462–S4s5

    Article  PubMed  Google Scholar 

  31. Mammen MJ, Scannapieco FA, Sethi S (2020) Oral-lung microbiome interactions in lung diseases. Periodontology 2000 83(1):234–241

    Article  PubMed  Google Scholar 

  32. Mendez R, Banerjee S, Bhattacharya SK, Banerjee S (2019) Lung inflammation and disease: a perspective on microbial homeostasis and metabolism. IUBMB Life 71(2):152–165

    Article  CAS  PubMed  Google Scholar 

  33. Metwally AA, Ascoli C, Turturice B, Rani A, Ranjan R, Chen Y et al (2020) Pediatric lung transplantation: dynamics of the microbiome and bronchiolitis obliterans in cystic fibrosis. J Heart Lung Transplant 39(8):824–834

    Article  PubMed  PubMed Central  Google Scholar 

  34. Moffatt MF, Cookson WO (2017) The lung microbiome in health and disease. Clin Med (Lond) 17(6):525–529

    Article  Google Scholar 

  35. Monsó E (2020) Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis. Arch Bronconeumol 56(1):5–6

    Article  PubMed  Google Scholar 

  36. Morris A, Gibson K, Collman RG (2014) The lung microbiome in idiopathic pulmonary fibrosis What does it mean and what should we do about it? Am J Respir Crit Care Med 190(8):850–852

    Article  PubMed  Google Scholar 

  37. Morton JT, Aksenov AA, Nothias LF, Foulds JR, Quinn RA, Badri MH et al (2019) Learning representations of microbe-metabolite interactions. Nat Methods 16(12):1306–1314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L et al (2018) Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathog 14(1):e1006798

    Article  PubMed  PubMed Central  Google Scholar 

  39. Mur LA, Huws SA, Cameron SJ, Lewis PD, Lewis KE (2018) Lung cancer: a new frontier for microbiome research and clinical translation. Ecancermedicalscience 12:866

    Article  PubMed  PubMed Central  Google Scholar 

  40. O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR et al (2019) Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med 199(9):1127–1138

    Article  PubMed  PubMed Central  Google Scholar 

  41. O’Dwyer DN, Garantziotis S (2021) The lung microbiome in health, hypersensitivity pneumonitis, and idiopathic pulmonary fibrosis: a heavy bacterial burden to bear. Am J Respir Crit Care Med 203(3):281–283

    Article  PubMed  PubMed Central  Google Scholar 

  42. Paudel KR, Dharwal V, Patel VK, Galvao I, Wadhwa R, Malyla V et al (2020) Role of lung microbiome in innate immune response associated with chronic lung diseases. Front Med 7:554

    Article  Google Scholar 

  43. Permall DL, Pasha AB, Chen XQ, Lu HY (2019) The lung microbiome in neonates. Turk J Pediatr 61(6):821–830

    Article  PubMed  Google Scholar 

  44. Quinn RA, Adem S, Mills RH, Comstock W, DeRight GL, Humphrey G et al (2019) Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome. Microbiome 7(1):23

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ramsey KA, Schultz A, Stick SM (2015) Biomarkers in paediatric cystic fibrosis lung disease. Paediatr Respir Rev 16(4):213–218

    PubMed  Google Scholar 

  46. Rogers GB, Bruce KD, Hoffman LR (2017) How can the cystic fibrosis respiratory microbiome influence our clinical decision-making? Curr Opin Pulm Med 23(6):536–543

    Article  PubMed  PubMed Central  Google Scholar 

  47. Saint-Criq V, Lugo-Villarino G, Thomas M (2021) Dysbiosis, malnutrition and enhanced gut-lung axis contribute to age-related respiratory diseases. Ageing Res Rev 66:101235

    Article  CAS  PubMed  Google Scholar 

  48. Salisbury ML, Han MK, Dickson RP, Molyneaux PL (2017) Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med 23(5):404–410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Scialo F, Amato F, Cernera G, Gelzo M, Zarrilli F, Comegna M et al (2021) Lung microbiome in cystic fibrosis. Life. 11(2):94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shukla SD, Budden KF, Neal R, Hansbro PM (2017) Microbiome effects on immunity, health and disease in the lung. Clin Transl Immunol 6(3):e133

    Article  Google Scholar 

  51. Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F et al (2019) The role of the Lung’s microbiome in the pathogenesis and progression of idiopathic pulmonary fibrosis. Int J Mol Sci 20(22):5618

    Article  CAS  PubMed Central  Google Scholar 

  52. Takahashi Y, Saito A, Chiba H, Kuronuma K, Ikeda K, Kobayashi T et al (2018) Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Res 19(1):34

    Article  PubMed  PubMed Central  Google Scholar 

  53. Tan JY, Tang YC, Huang J (2020) Gut microbiota and lung injury. Adv Exp Med Biol 1238:55–72

    Article  CAS  PubMed  Google Scholar 

  54. Tojo R, Suárez A, Clemente MG, de los Reyes-Gavilán CG, Margolles A, Gueimonde M et al (2014) Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 20(41):15163–15176

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tong X, Su F, Xu X, Xu H, Yang T, Xu Q et al (2019) Alterations to the lung microbiome in idiopathic pulmonary fibrosis patients. Front Cell Infect Microbiol 9:149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Torrisi SE, Kahn N, Vancheri C, Kreuter M (2020) Evolution and treatment of idiopathic pulmonary fibrosis. Presse Med. 49(2):104025

    Article  PubMed  Google Scholar 

  57. Tracy M, Cogen J, Hoffman LR (2015) The pediatric microbiome and the lung. Curr Opin Pediatr 27(3):348–355

    Article  PubMed  PubMed Central  Google Scholar 

  58. Trivedi R, Barve K (2020) Gut microbiome a promising target for management of respiratory diseases. Biochem J 477(14):2679–2696

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kashi Institute of Pharmacy, Varanasi, India

    Sachchidanand Pathak

  2. NIMS Institute of Pharmacy, Jaipur, India

    Anurag Mishra

  3. Suresh Gyan Vihar University, Jaipur, India

    Gaurav Gupta, Abhay Raizaday & Santosh Kumar Singh

  4. Limetta Laboratories, Haridwar, India

    Pramod Kumar

  5. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India

    Sachin Kumar Singh

  6. Department of Biotechnology, School of Engineering and Technology (SET), Sharda University, Greater Noida, India

    Neeraj Kumar Jha

  7. Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

    Dinesh Kumar Chellappan

  8. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

    Kamal Dua

  9. Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, Australia

    Kamal Dua

Authors
  1. Sachchidanand Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anurag Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaurav Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abhay Raizaday
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Santosh Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pramod Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sachin Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neeraj Kumar Jha
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dinesh Kumar Chellappan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kamal Dua
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India

    Gaurav Gupta

  2. School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia

    Brian G. Oliver

  3. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

    Kamal Dua

  4. School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India

    Alisha Singh

  5. R&D Science and Emerging Technologies, Aerogen Limited, Dangan, Ireland

    Ronan MacLoughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pathak, S. et al. (2022). Microbiome in Idiopathic Pulmonary Fibrosis. In: Gupta, G., Oliver, B.G., Dua, K., Singh, A., MacLoughlin, R. (eds) Microbiome in Inflammatory Lung Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-16-8957-4_13

Download citation

Publish with us

Policies and ethics

Search

Navigation